Why Madrigal Pharmaceuticals Stock Was Plummeting This Week

An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal Pharmaceuticals (NASDAQ: MDGL) stock out of the doldrums over the past few trading days. Investor expectations are clearly very high, as the company's share price had withered by nearly 20% week to date as of Friday before market open, according to data compiled by S&P Global Market Intelligence.Madrigal unveiled those figures Monday morning. The company said that its preliminary results indicated it earned $100 million to $103 million in the fourth quarter from Rezdiffra, its treatment for metabolic dysfunction-associated steatohepatitis (MASH, a type of fatty liver disease). Its full-year 2024 tally from the drug was pegged at $177 million to $180 million. At the end of the year, the company added, over 11,800 patients were taking the medication.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool